Clinical Efficacy and Quality of Life Study of Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia
黄芸芸 1邬秋 1徐晶晶1
扫码查看
点击上方二维码区域，可以放大扫码查看
作者信息
1. 562400 贵州兴义,黔西南州人民医院血液内科
折叠
摘要
目的 探讨对慢性髓系白血病(Chronic Myeloid Leukemia,CML)采用酪氨酸激酶抑制剂治疗的临床效果及对生活质量的影响.方法 选取2020年6月至2023年6月就诊于黔西南州人民医院的68例慢性髓系白血病患者,根据治疗方法的不同分为对照组与观察组,每组各34例.对照组接受达沙替尼治疗,观察组接受氟马替尼治疗.比较两组患者的治疗效果、复发率、治疗前后的生活质量和不良反应发生率.结果 观察组在治疗3个月和6个月时的早期分子学反应(Early Molecular Reactions,EMR)与主要分子学反应(Main Molecular Reactions,MMR)均高于对照组(EMR:75％ vs 60％,MMR:65％ vs 50％,P＜0.05).观察组的复发率明显低于对照组(10％vs25％,P＜0.05).两组患者在治疗6个月后的SF-36生活质量评分无显著差异(P＞0.05).观察组的消化道不良反应发生率高于对照组(30％vs 15％,P＜0.05),但皮疹和水肿发生率低于对照组(皮疹:5％vs 20％,水肿:10％ vs 25％,P＜0.05).两组患者的血液学不良反应无显著差异(P＞0.05).结论 氟马替尼在治疗慢性髓系白血病患者方面优于达沙替尼,尤其在降低复发率方面效果显著.两种药物均能改善患者的生活质量,但均存在不良反应.还需进一步进行长期随访研究,以全面评估其长期疗效和安全性.
Abstract
Objective To investigate the clinical efficacy of tyrosine kinase inhibitors(TKIs)in the treat-ment of chronic myeloid leukemia(CML)and their impact on quality of life.Methods 78 CML patients treated at Qianxinan Prefecture People's Hospital from June 2020 to June 2023 were selected and divided into the control group(n=34)and the observation group(n=34).The control group received sunitinib treatment,while the observa-tion group received flumatinib treatment.Treatment efficacy,recurrence rates,pre-and post-treatment quality of life,and incidence of adverse reactions were compared between the two groups.Results The observation group showed higher rates of early molecular response(EMR)and major molecular response(MMR)at 3 and 6 months of treatment compared to the control group(EMR:75％vs 60％,MMR:65％vs50％,P＜0.05).The recurrence rate in the observation group was notably lower compared to the control group(10％vs 25％,P＜0.05).After 6 months of treatment,there was no significant difference in SF-36 quality of life scores between the two groups(P＞0.05).The incidence of gastrointestinal adverse reactions in the observation group was higher than that in the control group(30％vs 15％,P＜0.05),but the incidences of rash and edema were lower in the observation group than those in the control group(rash:5％vs 20％,edema:10％vs 25％,P＜0.05).There was no significant difference in he-matologic adverse reactions between the two groups(P＞0.05).Conclusion Flumatinib is superior to sunitinib in treating CML patients,particularly in reducing recurrence rates.Both medications can improve patients'quality of life,though each has associated adverse reactions.Long-term follow-up studies are needed to comprehensively evaluate their long-term efficacy and safety.
维普
万方数据